SSA
PLRX icon

Schonfeld Strategic Advisors’s Pliant Therapeutics PLRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,582
Closed -$228K – 2418
2023
Q1 		$228K Buy
+8,582
New +$244K ﹤0.01% 1489
2022
Q4 		– Sell
-10,000
Closed -$209K – 2914
2022
Q3 		$209K Sell
10,000
-9,100
-48% -$174K ﹤0.01% 2308
2022
Q2 		$153K Buy
+19,100
New +$122K ﹤0.01% 1994

Other funds holding PLRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Schonfeld Strategic Advisors's PLRX Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 8,582 shares — an estimated $228K sold.

Schonfeld Strategic Advisors first reported a position in PLRX in Q2 2022 and held it in 3 quarters. The position peaked at $228K in Q1 2023. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

  • Schonfeld Strategic Advisors reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 8,582 Pliant Therapeutics shares in Q2 2023, an estimated $228K.
  • Schonfeld Strategic Advisors first reported a position in Pliant Therapeutics in Q2 2022 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Pliant Therapeutics position peaked at $228K in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.